Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.
about
Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid.Identification of small molecules with type I interferon inducing properties by high-throughput screening.IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cellsCodelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles.Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression.TLR3 agonists and proinflammatory antitumor activities.Functional RIG-I-like receptors control the survival of mesenchymal stem cellsNovel pharmacological modulators of autophagy and therapeutic prospects.Pattern recognition receptors: immune targets to enhance cancer immunotherapy.Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface.Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system.Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response.APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer.Chloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cells.
P2860
Q34438516-2806DE7E-7C3A-4D03-91BA-2AE650EBF869Q34473943-8D643AB1-C420-44AD-901D-1675CFFF0A0AQ35025256-B5BA8C19-6AEA-4BB6-A132-DEC2413A9C09Q35126624-92AC6CBC-E9A8-42C4-8095-CEE59FDB11BEQ36520822-72267DA6-9531-410A-A1B6-AF878823ABF9Q36932335-AE99AF10-D309-49D5-A4CB-080115C8E3B2Q37136200-E5C6B747-30A2-43BA-A6AF-C926ED3AF3F5Q37424134-D421A9D0-E99F-42C3-93EC-F07A2B77FD12Q38031895-07B25F29-6744-4CDE-B06A-E4663CADBF16Q38690773-7C1F1E2F-A7BA-47E9-B75B-68B21F0DF2D9Q38944791-C2ED5956-C59C-4D75-AEC7-BDE5AB735D0BQ38956034-C8995D1D-50E8-452E-A628-67E1D2AE7B28Q40516283-814B0C4E-2099-48FB-A311-6F491507B6DCQ42473854-23222E65-E1DC-42BB-A218-3E5CA759B012Q52728203-8C033937-A9F1-4572-88DF-76CA2515A4F7
P2860
Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@en
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@nl
type
label
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@en
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@nl
prefLabel
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@en
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@nl
P2093
P2860
P1476
Antitumor effects of cytoplasm ...... (I:C), on human breast cancer.
@en
P2093
Hiroyuki Monma
Mamoru Harada
Masayuki Itakura
Nanae Harashima
Shinji Okano
Touko Inao
Tsuneo Tanaka
Yoshitsugu Tajima
P2860
P2888
P304
P356
10.1007/S10549-011-1930-3
P407
P577
2011-12-28T00:00:00Z